Belite Bio
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular de...
Latest News
4 days ago · marketbeat.com
What Belite Bio (BLTE) Said on Its Q3 Earnings CallBelite Bio NASDAQ: BLTE is preparing for a potential U.S. launch of its Stargardt disease treatment tinlarebant ahead of a February 12, 2027, regulatory decision, while prioritizing that review over an interim analysis of a separate geographic atrophy study, executives said on the company's third-quarter earnings call.
4 days ago · seekingalpha.com
Belite Bio, Inc (BLTE) Q3 2026 Earnings Call TranscriptBelite Bio, Inc (BLTE) Q3 2026 Earnings Call Transcript
4 days ago · globenewswire.com
Belite Bio Reports Unaudited Third Quarter 2026 Financial Results and Provides a Corporate UpdateSAN DIEGO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the third quarter ended September 30, 2026, and provided a business update.
12 days ago · globenewswire.com
Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial ResultsSAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Thursday, November 12, 2026, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the third quarter ended September 30, 2026.
1 month ago · globenewswire.com
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1SAN DIEGO, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced Marketing Authorization Application (MAA) submissions to the regulatory authorities in Singapore, the United Kingdom, and Switzerland for tinlarebant in the treatment of Stargardt disease type 1 (STGD1). Tinlarebant is an investigational, once-daily oral therapy for the treatment of STGD1, a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. There are currently no approved treatment options for the disease in Singapore, the United Kingdom, or Switzerland.
2 months ago · globenewswire.com
Belite Bio Announces Oral Presentations at Two Upcoming Medical ConferencesSAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its data will be presented at the Innovate Retina conference being held on October 8, 2026, in New Orleans, Louisiana, and at the American Academy of Ophthalmology (AAO) 2026 being held on October 9-12, 2026, in New Orleans, Louisiana. Innovate Retina Presentation Details Session 1: Inherited Retinal Diseases (IRD) Title: What Is Coming to the Clinics: Tinlarebant for Stargardt Disease Presenter: Paul Bernstein, MD, PhD, Professor of Ophthalmology and Vice-Chair for Clinical and Basic Science Research at the Moran Eye Center, University of Utah Date and Time: October 8, 2026 3:04 – 3:07 p.m.
2 months ago · seekingalpha.com
Belite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptBelite Bio, Inc (BLTE) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
2 months ago · zacks.com
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden CrossBelite Bio, Inc. Sponsored ADR (BLTE) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, BLTE's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
2 months ago · globenewswire.com
Belite Bio Announces Submission of New Drug Application to the Ministry of Health, Labour, and Welfare in Japan under the Sakigake Designation System for Tinlarebant for the Treatment of Stargardt Disease Type 1SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- - Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the submission of a New Drug Application (NDA) to the Ministry of Health, Labour, and Welfare (MHLW) in Japan for tinlarebant in Stargardt disease type 1 (STGD1). Tinlarebant is an investigational, once-daily oral therapy for the treatment of STGD1, a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss. STGD1 affects an estimated 9,500 people in Japan alone, and there are currently no approved treatment options for the disease.
2 months ago · benzinga.com
Why Is Belite Bio Stock Soaring Friday?Belite Bio Inc. (NASDAQ:BLTE) drew a bullish initiation from Canaccord Genuity, which sees significant upside tied to the potential launch of its lead eye-disease drug, tinlarebant.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove BLTE